Implementing a Method for Evaluating Patient-Reported Outcomes Associated With Oral Oncolytic Therapy

“… 28 Oral oncolytics are associated with a wide array of adverse effects, and data indicate that patients who receive these treatments frequently experience moderate-to-severe symptoms. 29 To mitigate these and other adverse effects, it is imperative that providers diligently monitor patients who receive oral oncolytic therapy. For example, in a recent clinical trial, 766 patients were randomly assigned to use either a Web-based tool that enabled them to report adverse effects or standard-of-care reporting methods.…”

Section: Monitoring and Follow-upmentioning

confidence: 99%

“… 30 Use of patient-reported outcomes (PROs) in patients who receive oral oncolytic therapy is in the early phases of development, but one can assume that the benefits would be similar to those for patients who receive intravenous chemotherapy. 29 , 31 …”

Section: Monitoring and Follow-upmentioning

confidence: 99%

2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard

Mackler

Segal

Muluneh

et al. 2019

JOP

Self Cite

View full text Add to dashboard Cite

PURPOSE: The aim of the current work was to present a pharmacy practice standard from the Hematology/Oncology Pharmacy Association (HOPA) on the management of oral oncolytic therapy. METHODS: The HOPA Standards Committee organized a work group of oncology pharmacist specialists to create a pharmacy practice standard for the management of oral oncolytic therapy that describes the pharmacist’s role on the cancer care team, provides examples of practice tools and resources, summarizes current data related to outcomes, and discusses opportunities to enhance the care of patients with cancer who receive oral oncolytic therapy. We reviewed primary literature, including currently published oral oncolytic guidelines and HOPA’s Scope of Hematology/Oncology Pharmacy Practice. RESULTS: Management of oral oncolytic therapy was divided into the following primary areas: prescribing, education, dispensing and distribution, and monitoring and follow-up. Pharmacists’ roles were summarized in each area with a focus on interprofessional collaboration, communication, patient safety, and quality of patient care. Standards describe the best practices in each area ( Table 1 ). CONCLUSION: Multiple opportunities exist for pharmacists to enhance the care of patients with cancer who receive oral oncolytics through collaboration with oncology care team members. The role of the oncology pharmacist in the care of this patient population is critical given the complexities related to cost, tolerability, and safety of oral oncolytic medications; issues of access; and the monitoring and follow-up of patients receiving this therapy.

show abstract

“…However, it cannot be used to monitor all treatment toxicities because only 10 symptoms are assessed; the ESAS does not include digestive symptoms (eg, vomiting, diarrhea), cutaneous symptoms, fluid retention (eg, edema), or sepsis. However, its routine use was associated with a 6% increase in 1-year overall survival in a retrospective matched cohort study of 128,893 patients [ 20 - 22 ].…”

Section: Effectiveness Criteriamentioning

confidence: 99%

How Should Oncologists Choose an Electronic Patient-Reported Outcome System for Remote Monitoring of Patients With Cancer?

Denis¹,

Krakowski²

2021

J Med Internet Res

View full text Add to dashboard Cite

Electronic patient-reported outcome (ePRO) systems for symptom monitoring in patients with cancer have shown quality of life and survival benefits in controlled trials. They are beginning to be used in routine oncology practice. Many software developers provide software solutions for clinicians, but how should clinicians decide which system to use? We propose a synthesis of the main questions regarding the effectiveness, safety, and functionality of an ePRO system that a clinician should ask software providers to assist in the selection of a software product in order to obtain the best value tools for their patients and their practice.

show abstract

Implementing a Method for Evaluating Patient-Reported Outcomes Associated With Oral Oncolytic Therapy

Abstract: PROs can be evaluated through the use of a standardized tool, such as the ESAS-r, in oncology patients receiving oral oncolytic therapy. Implementing such a tool in both community and academic practices is feasible and may facilitate improvements in the quality of care.

Cited by 17 publications

References 11 publications

Baseline Edmonton Symptom Assessment System and Survival in Metastatic Renal Cell Carcinoma

Baseline Edmonton Symptom Assessment System and Survival in Metastatic Renal Cell Carcinoma

2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard

How Should Oncologists Choose an Electronic Patient-Reported Outcome System for Remote Monitoring of Patients With Cancer?

Contact Info

Product

Resources

About